Literature DB >> 25220672

Toward a better liver graft allocation that accounts for candidates with and without hepatocellular carcinoma.

C Toso1, V Mazzaferro, J Bruix, R Freeman, G Mentha, P Majno.   

Abstract

In some countries where the Model for End-Stage Liver Disease (MELD) score is used for graft allocation, selected patients with hepatocellular carcinoma (HCC) receive a fixed number of exception points at listing, and increasing priority on the list by accruing additional exception points at regular time intervals. This system originally aimed at balancing the risks of HCC patients of developing contraindications and of non-HCC patients of dying before transplantation, is not ideal because it appears to offer an advantage to HCC patients, regardless of tumor characteristics and response to loco-regional treatment. Scores modulated by HCC characteristics have been proposed. They are based on a more refined estimate of the risk of pretransplant drop-out or of the posttransplant transplant benefit expressed as the life-years gained for each graft. This review describes the newly proposed systems, and discusses their advantages and drawbacks. We believe that the current exception points allocation should be revised and that drop-out-equivalent or transplant benefit-equivalent models should be studied further. As with all policy changes, these should be done under close monitoring that allows subsequent revisions. © Copyright 2014 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Keywords:  Cancer/malignancy/neoplasia; clinical research/practice; liver disease: malignant; liver transplantation/hepatology; organ procurement and allocation

Mesh:

Year:  2014        PMID: 25220672     DOI: 10.1111/ajt.12923

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  18 in total

1.  Comparison of two equivalent model for end-stage liver disease scores for hepatocellular carcinoma patients using data from the United Network for Organ Sharing liver transplant waiting list registry.

Authors:  Sarah K Alver; Douglas J Lorenz; Kenneth Washburn; Michael R Marvin; Guy N Brock
Journal:  Transpl Int       Date:  2017-08-23       Impact factor: 3.782

2.  Twenty years of Milan criteria: how far do we go.

Authors:  Po-Chih Yang; Nobuhisa Akamatsu; Kiyoshi Hasegawa; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-12       Impact factor: 7.293

Review 3.  Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update.

Authors:  Masao Omata; Ann-Lii Cheng; Norihiro Kokudo; Masatoshi Kudo; Jeong Min Lee; Jidong Jia; Ryosuke Tateishi; Kwang-Hyub Han; Yoghesh K Chawla; Shuichiro Shiina; Wasim Jafri; Diana Alcantara Payawal; Takamasa Ohki; Sadahisa Ogasawara; Pei-Jer Chen; Cosmas Rinaldi A Lesmana; Laurentius A Lesmana; Rino A Gani; Shuntaro Obi; A Kadir Dokmeci; Shiv Kumar Sarin
Journal:  Hepatol Int       Date:  2017-06-15       Impact factor: 6.047

Review 4.  Liver transplantation for hepatocellular carcinoma from living-donor vs. deceased donor.

Authors:  Nobuhisa Akamatsu; Norihiro Kokudo
Journal:  Hepatobiliary Surg Nutr       Date:  2016-10       Impact factor: 7.293

5.  Hepatocellular carcinoma and liver transplant: beyond the Milan criteria and the risk of "short-blanket" syndrome.

Authors:  Stefano Gitto; Stefano Di Sandro; Paolo Magistri; Pietro Andreone; Fabrizio Di Benedetto
Journal:  Hepatobiliary Surg Nutr       Date:  2020-08       Impact factor: 7.293

6.  Saudi Association for the Study of Liver diseases and Transplantation practice guidelines on the diagnosis and management of hepatocellular carcinoma.

Authors:  Saleh A Alqahtani; Faisal M Sanai; Ashwaq Alolayan; Faisal Abaalkhail; Hamad Alsuhaibani; Mazen Hassanain; Waleed Alhazzani; Abdullah Alsuhaibani; Abdullah Algarni; Alejandro Forner; Richard S Finn; Waleed K Al-Hamoudi
Journal:  Saudi J Gastroenterol       Date:  2020-10       Impact factor: 2.485

7.  Expanding transplantation of patients with a liver cancer without harming allocation: a priority in the era of scarce donation.

Authors:  Massimo Colombo; Guido Torzilli
Journal:  Hepatobiliary Surg Nutr       Date:  2017-10       Impact factor: 7.293

Review 8.  Liver cancer: Approaching a personalized care.

Authors:  Jordi Bruix; Kwang-Hyub Han; Gregory Gores; Josep Maria Llovet; Vincenzo Mazzaferro
Journal:  J Hepatol       Date:  2015-04       Impact factor: 25.083

Review 9.  Selection of patients with hepatocellular cancer: a difficult balancing between equity, utility, and benefit.

Authors:  Alessandro Vitale; Quirino Lai
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21

Review 10.  Enlarged selection criteria for hepatocellular cancer: is the upper limit needed?

Authors:  Andrea Peloso; Graziano Oldani
Journal:  Transl Gastroenterol Hepatol       Date:  2017-09-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.